Secondary case-cohort analysis of the VISTA trial (96 recurrence cases, 192 subcohort) after a first VTE treated with VKAs: plasma proteomics during and after anticoagulation found no proteins significantly associated with VTE recurrence.
RCT
Smit et al. Plasma proteomics does not identify biomarkers of venous thromboembolism recurrence during and after anticoagulation: results from the VISTA study